X-Ray AnalysesConsumer DefensiveBritish American Tobacco p.l.c.
B

British American Tobacco p.l.c.

NYSE (ADR) · LSE: BATS: BTI·Tobacco·United Kingdom
Price at analysis
$60.56
▼ 1.9% · up ~2× from its 2024 lows
◆ The Buffett Lens
◆ Educational analysis & opinion — not investment advice. Figures as of 2 July 2026. See full disclaimer below.
The Scorecard · one-second read
Moat
7
Management & Capital
6
Financial Strength
6
Growth
4
Valuation & Yield
7
◆ Type · High-yield / deep valueBusiness · Wonderful economics, terrible tradeDividend · ~5.3% yield · paid for decades
6.2
"A wonderful business — in a business I would not want to own."
The perfect economics of tobacco · ~13× earnings, ~5.3% yield · declining volumes, heavy debt & an ESG stain · the easy money already made
Part I

The business, in plain English

What it does · how it got here · where it operates

Let me be plain about what this company does, because it is both very simple and very uncomfortable. British American Tobacco sells cigarettes and the nicotine products meant to replace them. It buys tobacco leaf for pennies, rolls it into a branded product that a addicted customer will buy every single day, and sells it for a price the customer barely questions. It is one of the most profitable business models human commerce has ever devised — and it kills its best customers. Both of those things are true, and an honest owner must hold them in the same hand.

Founded in 1902 and based in London, BAT is one of the two or three largest tobacco companies on earth outside China. It owns Dunhill, Kent, Lucky Strike, Rothmans and Pall Mall worldwide, and — since paying £42 billion for the rest of Reynolds American in 2017 — Newport, Camel and Natural American Spirit in the United States, now its single largest market. In the year to December 2025 it turned over £25.6 billion and earned about £7.8 billion in profit, at operating margins near 40%. The London-listed shares trade as BATS; most of the dividend-hungry world owns it through the BTI American deppositary receipt, at about $60.56 and roughly a $98 billion market value.

Operating cash flow, typical year
~£9–10B
on capex of barely £0.5B — a cash fountain
Dividend, paid & raised for
decades
~£5B mailed to owners every year
US brands write-down, 2023
≈ £25B
the admission that Western cigarettes are a shrinking asset

"I'll tell you why I like the cigarette business. It costs a penny to make. Sell it for a dollar. It's addictive. And there's fantastic brand loyalty." — a tobacco executive's boast, which Buffett quoted precisely because it is true

That sentence explains the numbers and the discomfort at once. The economics are close to perfect: negligible capital, a customer who returns daily by compulsion, and pricing power that lets the company raise prices every year to more than offset the volumes it steadily loses. And yet Buffett, who understood those economics better than anyone, chose not to own it — and I will come back to why, because it is the whole point of the letter at the end.

Founded1902 · London, United Kingdom
Sector / IndustryConsumer Defensive · Tobacco & Nicotine
ListingsLSE: BATS (£) · NYSE: BTI (ADR, $)
Key brandsDunhill, Kent, Lucky Strike, Newport, Camel · Vuse, glo, Velo
Revenue (FY2025)£25.6 B
Market capitalisation~$98 B (ADR)
Part II

The circle of competence

Why the economics are extraordinary — and whether you'd understand it

I can explain this business to a ten-year-old, though I would not enjoy doing so. Here is the whole machine, end to end:

01
Buy leaf for pennies
The raw material is a cheap agricultural crop.
02
Brand & roll it
Turn a commodity into Dunhill or Newport.
03
Sell to a daily habit
An addicted customer returns every day.
04
Raise price yearly
Nudge prices up faster than volume falls.
05
Mail the cash out
Tiny capex → ~£5B of dividends a year.
How hard is it to understand?
As simple as it gets · 5/5 — the value chain is trivial: a cheap, addictive, branded product bought daily at a price nobody negotiates. The difficulty in owning BAT is never intellectual. It is the durability of the demand and the conscience of the owner — not the plumbing of the business.

The honesty this business demands runs the other way from Coca-Cola's. Coke is easy to understand and its future is bright; BAT is easy to understand and its future is shrinking. Cigarette volumes in the rich world fall a few percent every year, and that decline is permanent — it will not reverse. The entire investment case rests on a single question: can price increases and new nicotine products offset falling volumes for long enough to keep the cash fountain running while you are paid an ~8% cash return (dividend plus buyback) to wait?

What you must believe to own it
  • Price beats volume, for years yet — BAT can keep raising prices faster than smokers quit, so revenue and cash hold up even as sticks decline.
  • The smokeless pivot works — Vuse, glo and Velo grow into a real, profitable second business before combustibles fade too far.
  • Litigation and regulation stay survivable — menthol bans, excise taxes and lawsuits trim the trade without shutting it down.
Part III

How it makes money

Combustibles cash cow · New Categories · geographic mix

Almost all of the profit still comes from the old, doomed, wonderful product — and a growing sliver from the things meant to replace it.

Combustibles (cigarettes) — the cash cow~79%
Dunhill, Kent, Lucky Strike, Newport, Camel. Declining volumes, but priced up every year. Still the engine. [mix approx.]
New Categories (Vuse, glo, Velo) — the pivot~13%
Vapour, heated tobacco & nicotine pouches. Now broadly profitable; the intended future. [approx.; FMP segment data understates this]
Traditional Oral (US moist snuff)~4%
Grizzly, Kodiak — a small, steady US business.
Other~4%
Wholesale, distribution and sundry.
Where in the world the money comes from
United States (via Reynolds)~40%
The largest single market — and the most exposed to a menthol ban. [geo split approx.; FMP data stale]
Rest of world (Europe, AME, APMEA)~60%
A globally diversified footprint across ~180 markets.
The pond it swims in (market figures approx.)
Shrinking
Global cigarette volumes
▼ a few % / year
Growing
Smokeless nicotine
▲ double digit
#1 / #2
BAT global position
ex-China

This is the rare pond that is draining. Humanity is, slowly and rightly, smoking less. BAT's task is not to grow the pond but to take a larger, richer share of it while steering its customers toward the smokeless products it also sells — Vuse (the world's leading vapour brand), glo (heated tobacco) and Velo (nicotine pouches). The company's stated ambition is to earn half its revenue from non-combustibles by 2035. Whether it gets there before the cigarette business fades is the entire game.

Part IV

The moat

A wide fortress built on a melting glacier

BAT has a genuine, wide moat — and it sits on ground that is slowly melting. Both halves matter.

The brand & the habit. A smoker does not shop on price between Newport and a no-name; the brand and the addiction together are one of the stickiest franchises in commerce. This is the intangible-asset moat in its purest, and least comfortable, form.

The advertising ban — the strangest moat of all. Because governments forbid tobacco advertising, no new brand can ever be built. That freezes the market in favour of the incumbents forever. Regulation, meant to hurt the industry, has handed its survivors a permanent barrier to entry. It is a moat carved by the state.

Distribution & scale. Getting a product into millions of corner shops across 180 markets, under the world's tightest regulatory regime, is a barrier a newcomer could not cross at any price.

How durable? A melting moat. Here is the honesty. The fortress walls are thick, but the ground beneath them is receding a few percent a year and will never stop. This is not Coca-Cola, whose moat widens into new drinks. It is closer to the newspapers Buffett once called "impregnable" — a franchise that was real, and lucrative, and quietly dying. The moat is wide. It is also, unmistakably, narrowing. You are being paid a fat dividend to stand inside it while it does.

Part V

The smokeless bet

"A Smokeless World" · Vuse, glo, Velo · can the second act arrive in time?

Every tobacco company now tells the same story — that it is becoming something cleaner — and an owner must weigh it with a cold eye. BAT's version is called "Building A Smokeless World," and unlike a slogan it has real revenue behind it. Three products carry the hope:

V
Vuse · Vapour (e-cigarettes)
The world's leading vapour brand by value. The largest of the New Categories — but under constant assault from cheap, illicit, single-use disposable vapes that flout the rules BAT must follow.
g
glo · Heated tobacco
Heats rather than burns tobacco. The category leader is Philip Morris's IQOS; glo is a determined #2 fighting for share in Europe and Japan.
V
Velo · Modern oral (nicotine pouches)
Tobacco-free nicotine pouches — the fastest-growing, highest-margin, and most promising of the three, especially in the US and Europe.

The encouraging news for an owner is that these are no longer a cash drain — the New Categories reached profitability, which is the moment a "transition story" stops being an expense and starts being a business. The sober news is the arithmetic of the race: combustibles still throw off the overwhelming majority of profit, and they are declining now, while the smokeless business — though growing smartly — is not yet remotely large enough to carry the company. The whole question is one of timing: can the new act grow up before the old one fades away? Nobody, including management, honestly knows. That uncertainty is why the stock is cheap.

Part VI

Management & capital allocation

The Reynolds mistake · the impairment · deleveraging, buybacks & the ITC sale

I judge managers above all on what they do with the cash — and BAT's record is a genuinely mixed one, worth telling honestly.

T
Tadeu Marroco · Chief Executive
A BAT finance lifer who took the top job in 2023 and immediately did the honest, painful thing: wrote down the US cigarette brands by ~£25B, admitting they are a declining asset. Since then, focused on deleveraging, cash generation and the smokeless pivot.
S
Soraya Benchikh · Finance Director
Steward of a balance sheet still carrying ~£31B of net debt and ~£87B of acquisition intangibles — and of the dividend and buyback that the cash fountain funds.
The one deal that shaped everything

In 2017 BAT paid £42 billion for the 58% of Reynolds American it did not already own — at the very top of the US cigarette market. It made America BAT's biggest market and loaded the balance sheet with debt and goodwill. Six years later, in 2023, the company wrote down those US brands by roughly £25 billion and swung to a £14.4 billion reported loss. In Buffett's language, a good part of that goodwill was "capitalised adrenaline" — the price of an over-eager acquisition, later confessed. It is the single most important fact about this management's capital allocation, and it argues for humility, not swagger.

What they're doing now — and skin in the game
Deleveraging + buyback
funded by the ITC sale
BAT has been trimming its long-held ~29% stake in India's ITC Ltd. and using the proceeds to cut net debt (from >3× to ~2.5× EBITDA) and begin buying back its own cheap shares — a rational use of cash at these prices.
Institutional holders
~30%
Capital Group ~9% · BlackRock ~6.5% · Fidelity ~6%. Notably, reclusive billionaire Kenneth Dart has been a large long-term holder. Insider open-market trades: none of note (UK filer).

The verdict on management is competent, chastened, and rational — not visionary. They overpaid once, badly, and have spent years cleaning it up: honest write-downs, falling debt, and buybacks that are genuinely smart when the shares trade this cheaply. That is the right playbook for the hand they hold. I would simply never forget the £25 billion lesson when they next feel the urge to do something big.

Part VII

The numbers

Financials in GBP · valuation multiples on the USD ADR · linked to the data pages

MetricValueRead
Revenue (FY2020 → FY2025)£25.8B → £25.6B◆ essentially flat
Reported EPS swing (2023 → 2025)−£6.49 → £3.51◆ 2023 = the impairment
Operating margin~40%▲ superb
Net profit margin~30%▲ rich
Return on equity (ROE)16.3%▲ solid
Return on invested capital (ROIC)8.1%◆ dragged by £87B goodwill
Net debt / EBITDA2.5x◆ high but falling
Interest coverage5.9x▲ comfortable
Free cash flow (typical yr)~£8B▲ gushes cash
Capex / revenue~2%▲ wonderfully asset-light
Goodwill & intangibles / assets~80%◆ almost all Reynolds

Two truths sit side by side here. First, the cash generation is magnificent: ~40% operating margins, ~£8–10 billion of operating cash flow on almost no capital, funding a dividend of ~£5 billion a year with room to spare. Second, the accounting returns look mediocre — an 8% ROIC — but that is an illusion created by the £87 billion of goodwill and brand value piled up buying Reynolds. Strip out that acquisition tombstone and the underlying cash return on the tangible business is enormous; this is the textbook case Buffett describes, where accounting goodwill masks a fabulous cash economics. The real caution flags are elsewhere: flat-to-declining revenue, and a balance sheet still carrying £31 billion of net debt and negative tangible equity. Strong cash, shrinking top line, meaningful leverage — read all three together.

Part VIII

Valuation

The widest gap between bulls and bears on the whole board

YardstickTodayRead
P/E — reported earnings~13xpriced as a declining franchise
Dividend yield~5.3%well-covered (~68% payout)
Total cash return (div + buyback)~8%you're paid handsomely to wait
Free cash flow yield~4.5%converts cleanly
EV / EBITDA10.4xcheap for the cash
Price / book2.1xbook is ~all intangible — ignore it
Two lenses, wildly apart
The market says
~13× · 5.3%
a melting ice cube — priced for permanent decline
A cash-flow DCF says ◆
~$184
the cash fountain, extrapolated → wildly cheap
A lone bearish analyst says
$40
thin coverage on the ADR — one voice, well below

I have not seen a wider disagreement anywhere on this board. A mechanical discounted-cash-flow model, fed BAT's enormous cash flows, spits out ~$184 — nearly triple the price — because it quietly assumes the cash lasts. A lone analyst covering the ADR sits at $40, assuming it doesn't. The market splits the difference at ~13× earnings and a 5.3% yield — the multiple Buffett's own framework assigns to a narrowing franchise. All three can't be right, and the honest answer is that the value depends entirely on how fast cigarettes decline and how well the smokeless pivot lands — which no model can know. What I can say is that the deep-value bargain of 2023–24 is largely gone: the stock has roughly doubled off its lows, and the ~8% yield has compressed to ~5.3%. What was a screaming cigar butt is now a fairly-valued, high-yield melting-ice-cube.

PRICE vs. VALUE — three views, far apart
Bear $40
Price $60
Cash-flow DCF ~$184
◀ Decline priced inCash extrapolated ▶
The truth lives somewhere in that wide gap and depends on the pace of decline — which is why the margin of safety is thinner than the headline yield suggests. After the doubling, this is fair value, not a bargain. I'd want weakness back toward the low $50s (a >6% yield, ~11× earnings) before calling it cheap again. → Interactive DCF model
Part IX

Risks & controversies

Decline · litigation · regulation · the ESG stain — with sources

📉 Permanent secular volume decline⚖️ Canada litigation (~£6B+ settlement)🚭 US menthol ban risk (hits Newport)🌫️ Illicit disposable vapes stealing Vuse share💷 £31B net debt · negative tangible equity🚫 ESG exclusion — many funds can't own it💱 FX drag (GBP reporting, global sales)

This is the most risk-laden name we have examined, and it deserves a clear eye. The secular decline of cigarettes is not a risk but a certainty; the only question is pace. Litigation is real and large — BAT's Canadian arm agreed to a multi-billion industry settlement that drove heavy 2024–25 charges and cash outflows. A US menthol ban would strike directly at Newport, a crown jewel of the Reynolds deal. And beyond the numbers sits the ESG stain: a large and growing pool of investors and funds simply will not — or cannot — own a tobacco company, which caps the buyer base and is part of why the stock stays cheap. None of these is likely to be fatal to the cash flows this decade. All of them are reasons the market pays only ~13× for them.

PART X · To our shareholders
The Letter

Dear shareholder — this is the hardest letter I have written to you, not because the business is complicated, but because it is simple in a way that troubles the conscience. So let me separate, as I always try to, the two questions that must never be blurred: is this a wonderful business? and is this a business I want to own?

On the first question, the answer is almost embarrassingly clear. British American Tobacco has some of the finest economics I have ever studied. It takes a cheap leaf, wraps it in a beloved old brand, and sells it to a customer who is compelled to come back tomorrow — at a price he does not argue with, and which the company lifts a little every year. It costs almost nothing in capital to run, so nearly every pound it earns can be mailed straight to owners. An advertising ban that was meant to punish the industry has instead frozen out all new competition forever. On the cold arithmetic of return on capital, this is a franchise most companies would kill for.

And yet I must tell you the second truth, because it is the more important one. The ground under this fortress is melting. Cigarette volumes fall a little every year and will never rise again — this is not a cycle to wait out, it is a tide going out for good. Management's answer, the smokeless pivot into Vuse, glo and Velo, is real and finally profitable, but it is nowhere near large enough yet to carry the company, and the race between the fading old business and the growing new one is one that nobody — not you, not I, not the chief executive — can honestly handicap. Add to that a balance sheet still groaning under thirty billion pounds of debt from an acquisition they plainly overpaid for, and you have a wonderful cash machine bolted to a shrinking foundation.

Then there is the part no spreadsheet captures. Many years ago, when the great tobacco businesses were on offer at a song, I said something I have never taken back: I understood exactly why the economics were superb, and I chose not to own them anyway. There are things a person can do and things a person would rather not, and for me this fell on the wrong side of that line. I tell you this not to lecture — you are a grown investor and this is your decision, not mine — but because the ESG stain is also a hard financial fact: a whole universe of buyers is barred from ever owning this stock, and that is part of why it stays cheap and may always be.

So where does that leave us on price? The screaming bargain of two years ago is gone — the shares have roughly doubled, and the yield that once neared nine per cent has settled to a still-generous five-point-three. At about thirteen times earnings you are being paid an ~8% total cash return to stand inside a narrowing moat — a fair deal, not a steal. For the income investor who has made his peace with what this company sells and accepts that its best days of decline-defiance are priced in, it is a reasonable, well-covered, eyes-open holding. I would want it cheaper — back in the low fifties, where the yield tops six per cent — before I called it a bargain again. And I would size it as what it is: a high-yield melting ice cube, not a compounder to leave to my grandchildren. That, at least, is a distinction Coca-Cola never forced me to make.

With candour, and a clear conscience about the candour,— The Dividend Line Desk
The Bull Case
Extraordinary economics — ~40% operating margins, tiny capex, and an addicted customer base give a cash fountain funding an ~8% total cash return (5.3% dividend + buyback).
Genuinely cheap on cash — ~13× earnings, 10× EV/EBITDA, ~4.5% FCF yield, and a well-covered dividend paid for decades; the ESG discount is the buyer's edge.
A real, profitable second act — Vuse, glo and Velo have crossed into profit, and deleveraging plus buybacks show rational, chastened capital allocation.
The Bear Case
Permanent decline — cigarette volumes fall every year and never recover; the whole thesis is a race the smokeless business may not win in time.
Heavy legacy of one bad deal — £42B for Reynolds at the top led to a ~£25B write-down, ~£31B of net debt and negative tangible equity.
Litigation + regulation + ESG — a multi-billion Canadian settlement, US menthol-ban risk, and a permanent exclusion from a huge pool of investors.
Income — Eyes OpenA wonderful cash machine in a declining, ethically fraught trade. For income investors who accept what it sells, a reasonable, well-covered ~5.3% holder — but a melting ice cube, not a forever-compounder. Fairly valued after doubling; I'd want the low $50s (>6% yield) to call it cheap.
Want to be alerted if BTI dips toward the buy zone? Add the $52 price trigger to your Watchlist.
The Buffett Lens · Dividend Line Research · As of 2 Jul 2026 · Price $60.56 (BTI ADR)
Disclaimer: This analysis is educational opinion, not personalised financial advice or a recommendation to buy or sell. Figures reflect 2 Jul 2026 and may be out of date; financials are reported in GBP while the BTI ADR trades in USD, and items marked “approx.” are estimates. Do your own research and, where appropriate, consult a licensed professional before making any investment decision.
Dividend Line · X-Ray Analyses — written in the house methodology